logo-loader
viewNovavax, Inc.

Novavax to start human trials for Covid-19 vaccine candidate in Australia

Results of the first portion of trials are expected for July

Novavax, Inc. - Novavax to start human trials for Covid-19 vaccine candidate in Australia

Novavax Inc (NASDAQ:NVAX) said it enrolled the first participants to start clinical trials for its Covid-19 vaccine candidate.

The US biotech has developed NVX‑CoV2373, a protein to enhance immune responses and stimulate antibodies.

READ: Coronavirus: What’s happening in the labs of pharma companies worldwide

The first phase of clinical trials will be conducted in two parts: initially with 130 healthy participants in Australia aged between 18 to 59, then in another pool of individuals in a broader age range and geography.

Results of the first part are expected for July.

The trial is partly funded by the Coalition for Epidemic Preparedness Innovations (CEPI)

“The vaccine news has been the spark that was needed to push stock markets above and beyond month-long sideways ranges,” commented London Capital Group’s Jasper Lawler.

Shares surged 19% to US$54.79 in premarket trading.

Quick facts: Novavax, Inc.

Price: 81.64 USD

NASDAQ:NVAX
Market: NASDAQ
Market Cap: $4.79 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO PLC: Elevator Pitch

IXICO PLC's (LON:IXI) CEO Giulio Cerroni pitches the company to investors. The company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. For more information visit www.ixico.com

2 days, 9 hours ago

2 min read